Q1 EPS Estimate for Vertex Pharmaceuticals Raised by Analyst

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) - Equities research analysts at Zacks Research boosted their Q1 2027 earnings per share estimates for Vertex Pharmaceuticals in a research report issued on Wednesday, April 23rd. Zacks Research analyst R. Department now anticipates that the pharmaceutical company will post earnings of $4.24 per share for the quarter, up from their prior forecast of $4.23. The consensus estimate for Vertex Pharmaceuticals' current full-year earnings is $15.63 per share.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%.

A number of other research firms have also commented on VRTX. Bank of America lifted their price objective on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. Barclays boosted their price target on Vertex Pharmaceuticals from $435.00 to $467.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 11th. Wells Fargo & Company lowered Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 price target on the stock. in a research note on Thursday, January 30th. HC Wainwright reissued a "buy" rating and issued a $550.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Finally, Scotiabank boosted their price target on Vertex Pharmaceuticals from $433.00 to $450.00 and gave the company a "sector perform" rating in a research note on Tuesday, February 11th. Ten analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $514.91.

Vertex Pharmaceuticals Trading Up 0.4 %

Shares of Vertex Pharmaceuticals stock traded up $1.86 during midday trading on Friday, reaching $505.36. The company had a trading volume of 406,656 shares, compared to its average volume of 1,337,033. The stock has a fifty day moving average price of $490.74 and a 200 day moving average price of $466.65. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The firm has a market cap of $129.92 billion, a PE ratio of -229.71, a P/E/G ratio of 2.11 and a beta of 0.50. Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88.

Institutional Trading of Vertex Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Advisory Resource Group raised its position in shares of Vertex Pharmaceuticals by 3.2% in the third quarter. Advisory Resource Group now owns 1,970 shares of the pharmaceutical company's stock valued at $916,000 after purchasing an additional 61 shares during the period. Anchor Investment Management LLC raised its position in shares of Vertex Pharmaceuticals by 1,352.3% in the third quarter. Anchor Investment Management LLC now owns 1,583 shares of the pharmaceutical company's stock valued at $736,000 after purchasing an additional 1,474 shares during the period. World Investment Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $24,280,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $2,187,000. Finally, Destination Wealth Management raised its position in shares of Vertex Pharmaceuticals by 4.5% in the third quarter. Destination Wealth Management now owns 3,361 shares of the pharmaceutical company's stock valued at $1,563,000 after purchasing an additional 144 shares during the period. Institutional investors own 90.96% of the company's stock.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the sale, the executive vice president now owns 26,512 shares of the company's stock, valued at approximately $13,256,000. The trade was a 10.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Ourania Tatsis sold 530 shares of Vertex Pharmaceuticals stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $475.34, for a total transaction of $251,930.20. Following the completion of the sale, the executive vice president now directly owns 58,539 shares in the company, valued at approximately $27,825,928.26. This represents a 0.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 4,315 shares of company stock valued at $2,121,012 over the last ninety days. Corporate insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.